Equities

Luye Pharma Group Ltd

Luye Pharma Group Ltd

Actions
  • Price (EUR)0.324
  • Today's Change-0.002 / -0.61%
  • Shares traded0.00
  • 1 Year change-13.37%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6,1065,5445,510
Total Receivables, Net2,5922,2662,388
Total Inventory828773746
Prepaid expenses193551417
Other current assets, total9841,6521,335
Total current assets10,70310,78610,397
Property, plant & equipment, net5,1554,9094,594
Goodwill, net1,0421,003985
Intangibles, net6,3185,9855,442
Long term investments1,9681,114582
Note receivable - long term--8.608.38
Other long term assets------
Total assets25,49124,25022,582
LIABILITIES
Accounts payable427418323
Accrued expenses747686430
Notes payable/short-term debt4,9084,8654,987
Current portion long-term debt/capital leases6282,117523
Other current liabilities, total1,4281,4011,066
Total current liabilities8,1389,4877,330
Total long term debt3,2282,2654,228
Total debt8,7649,2479,738
Deferred income tax475658
Minority interest997866626
Other liabilities, total5491,4001,853
Total liabilities12,96014,07414,094
SHAREHOLDERS EQUITY
Common stock486457456
Additional paid-in capital4,1593,0771,716
Retained earnings (accumulated deficit)7,4556,9106,280
Treasury stock - common0(280)(280)
Unrealized gain (loss)(12)(1)1.92
Other equity, total44313314
Total equity12,53110,1768,488
Total liabilities & shareholders' equity25,49124,25022,582
Total common shares outstanding3,7623,5303,521
Treasury shares - common primary issue02020
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.